Home Cart Sign in  
Chemical Structure| 1532533-67-7 Chemical Structure| 1532533-67-7

Structure of Umbralisib
CAS No.: 1532533-67-7

Chemical Structure| 1532533-67-7

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

RP-5264 is an orally available, next generation PI3Kdelta inhibitor, inhibits PI3Kδ activity in enzyme and cell based assays with IC50 and EC50 values of 22.2 and 24.3 nM respectively.

Synonyms: TGR-1202; RP-5264; RP5264

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Umbralisib

CAS No. :1532533-67-7
Formula : C31H24F3N5O3
M.W : 571.55
SMILES Code : O=C1C(C2=CC=CC(F)=C2)=C([C@@H](N3N=C(C4=CC=C(OC(C)C)C(F)=C4)C5=C(N)N=CN=C53)C)OC6=C1C=C(F)C=C6
Synonyms :
TGR-1202; RP-5264; RP5264
MDL No. :MFCD28386165
InChI Key :IUVCFHHAEHNCFT-INIZCTEOSA-N
Pubchem ID :72950888

Safety of Umbralisib

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H332-H335
Precautionary Statements:P261-P280-P305+P351+P338

Related Pathways of Umbralisib

PI3K-AKT

Isoform Comparison

Biological Activity

Target
  • p110δ

    PI3Kδ, IC50:22.2 nM

In Vitro:

Cell Line
Concentration Treated Time Description References
CLL patient T cells 1 μM 72 hours To evaluate the effects of PI3K inhibitors on T cells from CLL patients. Results showed that Umbralisib better maintained Treg numbers and expression of immunosuppressive markers compared to idelalisib and duvelisib. Blood Adv. 2020 Jul 14;4(13):3072-3084.
Normal human T cells 0.1 to 10 μM 24 hours To evaluate the effects of PI3K inhibitors on T cell survival and function. Results showed that Umbralisib did not affect T cell survival at concentrations of 0.1 to 10 μM and better maintained Treg numbers and function compared to idelalisib and duvelisib. Blood Adv. 2020 Jul 14;4(13):3072-3084.
Chronic lymphocytic leukemia cells 1 nM - 10000 nM 72 hours To evaluate the effect of Umbralisib on CLL cell viability, results showed that pan-PI3Ki were most effective at inhibiting cell viability and PI3K signaling. Clin Cancer Res. 2022 Oct 14;28(20):4444-4455.
CMML patient bone marrow mononuclear cells 0.3-14 μM 72 hours Evaluate the growth inhibitory effect of Umbralisib on CMML patient bone marrow mononuclear cells, showing GI50 values between 0.3-14 μM in most samples. Exp Hematol. 2021 May;97:57-65.e5.
Daudi cells 1 µM 24 hours To evaluate the effect of Umbralisib in combination with the anti-CD20 antibody ublituximab on ADCC and ADCP activities in B-cell lymphoma cells. Results showed that the U2 combination (ublituximab + umbralisib) significantly enhanced ADCC and ADCP activities. Front Immunol. 2023 Apr 21;14:1130052.
Raji cells 1 µM 24 hours To evaluate the effect of Umbralisib in combination with the anti-CD20 antibody ublituximab on ADCC and ADCP activities in B-cell lymphoma cells. Results showed that the U2 combination (ublituximab + umbralisib) significantly enhanced ADCC and ADCP activities. Front Immunol. 2023 Apr 21;14:1130052.
Murine splenocytes 1 µM 6 hours To evaluate the effect of Umbralisib on murine T-cell activation, results showed that Umbralisib reduced CD69 expression in CD4+ and CD8+ T cells. Hemasphere. 2023 Feb 22;7(3):e840.
Human PBMCs 1 µM 72 hours To evaluate the effect of Umbralisib on T-cell proliferation, results showed that Umbralisib reduced T-cell proliferation. Hemasphere. 2023 Feb 22;7(3):e840.
Human PBMCs 1 µM 6 hours To evaluate the effect of Umbralisib on T-cell activation, results showed that Umbralisib reduced CD69 expression in CD4+ and CD8+ T cells. Hemasphere. 2023 Feb 22;7(3):e840.
THP-1 cells 10 μM 72 hours Evaluate the growth inhibitory effect of Umbralisib on THP-1 cells, showing THP-1 was less sensitive to Umbralisib. Exp Hematol. 2021 May;97:57-65.e5.

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
NSG mice Burkitt lymphoma xenograft model Oral 150 mg/kg Twice daily for 17 days To evaluate the antitumor effect of Umbralisib in combination with the anti-CD20 antibody ublituximab in a Burkitt lymphoma xenograft model. Results showed that the U2 combination (ublituximab + umbralisib) significantly inhibited tumor growth. Front Immunol. 2023 Apr 21;14:1130052.
Sprague-Dawley (SD) rats Rat plasma pharmacokinetic model Oral 80 mg/kg Single dose To evaluate the effect of sophocarpine on the pharmacokinetics of umbralisib. Results showed that sophocarpine significantly reduced AUC0→∞ and Cmax of umbralisib and increased CLz/F. Front Pharmacol. 2022 Jan 20;13:749095

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT03178201 Follicular Lymphoma PHASE2 TERMINATED 2020-06-30 Columbia University Medical Ce... More >>nter, New York, New York, 10019, United States Less <<
NCT03364231 Marginal Zone Lymphoma|Waldens... More >>trom Macroglobulinemia|Non Follicular Indolent Non-Hodgkin Lymphoma Less << PHASE2 COMPLETED 2022-02-15 TG Therapeutics Investigationa... More >>l Trial Site, Washington, District of Columbia, 20007, United States|TG Therapeutics Investigational Trial Site, Boston, Massachusetts, 02215, United States|TG Therapeutics Investigational Trial Site, Hackensack, New Jersey, 07601, United States|TG Therapeutics Investigational Trial Site, New York, New York, 10065, United States Less <<
NCT02742090 Chronic Lymphocytic Leukemia PHASE2 TERMINATED 2021-06-10 TG Therapeutics Investigationa... More >>l Trial Site, Huntsville, Alabama, 35805, United States|TG Therapeutics Investigational Trial Site, Washington, District of Columbia, 20007, United States|TG Therapeutics Investigational Trial Site, Fort Myers, Florida, 33916, United States|TG Therapeutics Investigational Trial Site, Saint Petersburg, Florida, 33705, United States|TG Therapeutics Investigational Trial Site, Kansas City, Missouri, 64132, United States|TG Therapeutics Investigational Trial Site, Lebanon, New Hampshire, 03756, United States|TG Therapeutics Investigational Trial Site, Hackensack, New Jersey, 07601, United States|TG Therapeutics Investigational Trial Site, New Hyde Park, New York, 11042, United States|TG Therapeutics Investigational Trial Site, New York, New York, 10032, United States|TG Therapeutics Investigational Trial Site, Rochester, New York, 14642, United States|TG Therapeutics Investigational Trial Site, Durham, North Carolina, 27710, United States|TG Therapeutics Investigational Trial Site, Hershey, Pennsylvania, 17033, United States|TG Therapeutics Investigational Trial Site, Philadelphia, Pennsylvania, 19146, United States|TG Therapeutics Investigational Trial Site, Nashville, Tennessee, 37203, United States|TG Therapeutics Investigational Trial Site, Seattle, Washington, 98104, United States Less <<
NCT01767766 Non-Hodgkin's Lymphoma|Chronic... More >> Lymphocytic Leukemia|Peripheral T-Cell Lymphoma|Hodgkin's Lymphoma Less << PHASE1 COMPLETED 2025-02-18 TG Therapeutics Trial Site, Sa... More >>rasota, Florida, 34232, United States|TG Therapeutics Trial Site, Hackensack, New Jersey, 07601, United States|TG Therapeutics Trial Site, New York, New York, 10019, United States|TG Therapeutics Trial Site, Durham, North Carolina, 27710, United States|TG Therapeutics Trial Site, Cincinnati, Ohio, 45242, United States|TG Therapeutics Trial Site, Nashville, Tennessee, 37203, United States|TG Therapeutics Investigational Trial Site, Milwaukee, Wisconsin, 53226, United States Less <<
NCT04163718 Chronic Lymphocytic Leukemia PHASE2 TERMINATED 2022-10-19 H. Lee Moffitt Cancer Center &... More >> Research Institute, Tampa, Florida, 33612, United States Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.75mL

0.35mL

0.17mL

8.75mL

1.75mL

0.87mL

17.50mL

3.50mL

1.75mL

References

 

Historical Records

Categories